SG10202006318TA - Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition - Google Patents
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute conditionInfo
- Publication number
- SG10202006318TA SG10202006318TA SG10202006318TA SG10202006318TA SG10202006318TA SG 10202006318T A SG10202006318T A SG 10202006318TA SG 10202006318T A SG10202006318T A SG 10202006318TA SG 10202006318T A SG10202006318T A SG 10202006318TA SG 10202006318T A SG10202006318T A SG 10202006318TA
- Authority
- SG
- Singapore
- Prior art keywords
- adm
- antibody
- acute
- adrenomedullin
- scaffold
- Prior art date
Links
- 208000030090 Acute Disease Diseases 0.000 title 1
- 208000017667 Chronic Disease Diseases 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
- 206010053159 Organ failure Diseases 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 230000004768 organ dysfunction Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001144—Hormones, e.g. calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11189447 | 2011-11-16 | ||
| EP12160014 | 2012-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202006318TA true SG10202006318TA (en) | 2020-08-28 |
Family
ID=48429015
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201801919QA SG10201801919QA (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| SG10202006318TA SG10202006318TA (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| SG11201402366PA SG11201402366PA (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201801919QA SG10201801919QA (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402366PA SG11201402366PA (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20140328853A1 (pt) |
| EP (3) | EP2780369B1 (pt) |
| JP (2) | JP6193871B2 (pt) |
| AU (1) | AU2012338731B2 (pt) |
| DK (2) | DK3553084T3 (pt) |
| ES (2) | ES2938653T3 (pt) |
| FI (1) | FI3553084T3 (pt) |
| HR (2) | HRP20230146T1 (pt) |
| HU (2) | HUE061696T2 (pt) |
| LT (2) | LT2780369T (pt) |
| NZ (1) | NZ624873A (pt) |
| PL (2) | PL3553084T3 (pt) |
| PT (2) | PT3553084T (pt) |
| RS (2) | RS64060B1 (pt) |
| SG (3) | SG10201801919QA (pt) |
| SI (1) | SI3553084T1 (pt) |
| WO (1) | WO2013072511A1 (pt) |
| ZA (2) | ZA201403552B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015092021A1 (en) * | 2013-12-20 | 2015-06-25 | Spingotec Therapeutics Gmbh | Adrenomedullin binder for use in therapy of cancer |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| WO2018109228A1 (en) * | 2016-12-16 | 2018-06-21 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| JP2021500548A (ja) | 2017-10-18 | 2021-01-07 | アドレノメト アクチェンゲゼルシャフト | 抗アドレノメデュリン（ａｄｍ）結合剤での処置下での治療モニタリング |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| EP4111204A1 (en) | 2020-02-27 | 2023-01-04 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
| BR112022016843A2 (pt) | 2020-02-27 | 2022-10-11 | Adrenomed Ag | Ligante antiadrenomedulina (adm) para uso na terapia de pacientes em choque |
| IL295728A (en) | 2020-02-27 | 2022-10-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm backbone without ig for use in the treatment of cure or prevention of shock |
| JP2023518380A (ja) * | 2020-03-16 | 2023-05-01 | アドレノメト アクチェンゲゼルシャフト | コロナウイルスに感染した患者におけるプロアドレノメデュリンまたはそのフラグメント、およびアドレノメデュリンに対する結合剤による治療 |
| CN111627559B (zh) * | 2020-06-17 | 2023-08-29 | 北京大学第三医院（北京大学第三临床医学院） | 预测患者死亡风险的系统 |
| WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
| WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6320022B1 (en) * | 1995-08-18 | 2001-11-20 | The United States Of America As Represented By The Department Of Health And Human Services | Adrenomedullin peptides |
| CA2242308A1 (en) | 1997-12-08 | 1999-06-08 | Smithkline Beecham Laboratoires Pharmaceutiques | Novel compounds |
| DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| EP1214600B1 (en) * | 1999-09-10 | 2005-12-21 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Determination of adrenomedullin-binding proteins |
| AU2002305394A1 (en) | 2001-05-04 | 2002-11-18 | Biosite, Inc. | Diagnostic markers of acute coronary syndromes and methods of use thereof |
| DE60238541D1 (de) | 2001-08-30 | 2011-01-20 | Biorexis Pharmaceutical Corp | Modifizierte transferrin-fusionsproteine |
| US6864237B2 (en) | 2002-05-17 | 2005-03-08 | Ping Wang | Treatment of shock using adrenomedullin and adrenomedullin binding protein-1 |
| EP1941867B1 (en) | 2002-06-07 | 2011-10-12 | Dyax Corp. | Modified kunitz domain polypeptide |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| WO2004097423A1 (en) | 2003-04-25 | 2004-11-11 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| US6884781B2 (en) | 2003-05-16 | 2005-04-26 | Ping Wang | Treatment of shock using adrenomedullin binding protein-1 |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20070280886A1 (en) | 2004-09-09 | 2007-12-06 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| JP4976412B2 (ja) | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
| US7825217B2 (en) | 2006-09-15 | 2010-11-02 | University Of Kansas Medical Center | Polypeptides for bone mineralization |
| BRPI0818810A2 (pt) * | 2007-10-31 | 2014-10-29 | Medimmune Llc | Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável. |
| ATE527353T1 (de) | 2007-12-19 | 2011-10-15 | Affibody Ab | Pdgf-bindendes polypeptid aus protein a |
| DK2358746T3 (da) | 2008-11-03 | 2020-12-21 | Molecular Partners Ag | Bindingsproteiner til inhibering af vegf-a-receptorinteraktionen |
| RU2550272C2 (ru) | 2009-08-27 | 2015-05-10 | Коваген Аг | Новые il-17-связывающие соединения и их медицинское применение |
| RU2556820C2 (ru) | 2009-12-14 | 2015-07-20 | Сцил Протеинс Гмбх | Модифицированные убиквитиновые белки со специфической связывающей активностью для экстрадомена "в" фибронектина |
| DE102010040035A1 (de) | 2010-03-04 | 2011-09-08 | Robert Bosch Gmbh | Verbesserungen der Rückwärts-Analyse zur Bestimmung von Fehlermaskierungsfaktoren |
| PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| FR2964103B1 (fr) | 2010-08-30 | 2018-11-23 | Universite D'aix-Marseille | Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament |
| MY174877A (en) | 2011-11-16 | 2020-05-20 | Adrenomed Ag | Anti-adrenomedullin (adm) antibpdy or anti-adm antibody fragment of anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic of acute disease or acute condition |
-
2012
- 2012-11-16 EP EP12784631.9A patent/EP2780369B1/en active Active
- 2012-11-16 JP JP2014541695A patent/JP6193871B2/ja active Active
- 2012-11-16 SG SG10201801919QA patent/SG10201801919QA/en unknown
- 2012-11-16 RS RS20230115A patent/RS64060B1/sr unknown
- 2012-11-16 DK DK19162009.5T patent/DK3553084T3/da active
- 2012-11-16 PL PL19162009.5T patent/PL3553084T3/pl unknown
- 2012-11-16 RS RS20190738A patent/RS58880B1/sr unknown
- 2012-11-16 ES ES19162009T patent/ES2938653T3/es active Active
- 2012-11-16 FI FIEP19162009.5T patent/FI3553084T3/fi active
- 2012-11-16 US US14/358,334 patent/US20140328853A1/en not_active Abandoned
- 2012-11-16 ES ES12784631T patent/ES2729710T3/es active Active
- 2012-11-16 SI SI201232021T patent/SI3553084T1/sl unknown
- 2012-11-16 AU AU2012338731A patent/AU2012338731B2/en active Active
- 2012-11-16 PL PL12784631T patent/PL2780369T3/pl unknown
- 2012-11-16 EP EP21216077.4A patent/EP4086283A1/en active Pending
- 2012-11-16 LT LTEP12784631.9T patent/LT2780369T/lt unknown
- 2012-11-16 DK DK12784631.9T patent/DK2780369T3/da active
- 2012-11-16 EP EP19162009.5A patent/EP3553084B1/en active Active
- 2012-11-16 PT PT191620095T patent/PT3553084T/pt unknown
- 2012-11-16 PT PT12784631T patent/PT2780369T/pt unknown
- 2012-11-16 LT LTEP19162009.5T patent/LT3553084T/lt unknown
- 2012-11-16 HU HUE19162009A patent/HUE061696T2/hu unknown
- 2012-11-16 SG SG10202006318TA patent/SG10202006318TA/en unknown
- 2012-11-16 NZ NZ624873A patent/NZ624873A/en unknown
- 2012-11-16 HR HRP20230146TT patent/HRP20230146T1/hr unknown
- 2012-11-16 HU HUE12784631 patent/HUE044383T2/hu unknown
- 2012-11-16 SG SG11201402366PA patent/SG11201402366PA/en unknown
- 2012-11-16 WO PCT/EP2012/072930 patent/WO2013072511A1/en active Application Filing
-
2014
- 2014-05-15 ZA ZA2014/03552A patent/ZA201403552B/en unknown
-
2016
- 2016-02-16 US US15/044,474 patent/US10221238B2/en active Active
-
2017
- 2017-05-17 JP JP2017098527A patent/JP2017155051A/ja active Pending
-
2018
- 2018-09-20 US US16/136,892 patent/US10800842B2/en active Active
- 2018-12-10 US US16/214,963 patent/US11673949B2/en active Active
-
2019
- 2019-06-04 HR HRP20191010TT patent/HRP20191010T1/hr unknown
- 2019-09-30 ZA ZA2019/06427A patent/ZA201906427B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906427B (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition | |
| SG11201402362VA (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| HRP20190122T1 (hr) | Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću | |
| MY174877A (en) | Anti-adrenomedullin (adm) antibpdy or anti-adm antibody fragment of anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic of acute disease or acute condition | |
| HK1202127A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy (adm) adm adm ig | |
| ZA201403549B (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| EP2164505A4 (en) | TREATMENT OF CHRONIC LUNG DISEASE | |
| IL216804A0 (en) | Methods for treating chronic kidney disease | |
| HK1159104A1 (zh) | 慢性腎功能衰竭處置劑 | |
| HK1198947A1 (en) | Thromboembolism preventive therapeutic agent for thromboembolism patients having severe renal dysfunction | |
| GB0816025D0 (en) | Medicament for the treatment of chronic obstructive pulmonary disease (COPD) | |
| TH107841B (th) | องค์ประกอบทางเภสัชกรรมสำหรับการป้องกันหรือการรักษาโรคปอดอุดตันแบบเรื้อรัง |